Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026)

Protalix BioTherapeutics has reported Raw Materials for 11 years, with the latest figure at $6.1 million in Q2 2026.

• On a quarterly basis, Raw Materials rose 39.61% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $6.1 million, a 39.61% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 31.46% from the prior year.
• Raw Materials was $6.1 million for Q2 2026 at Protalix BioTherapeutics, up from $6.0 million in the prior quarter.
• The five-year high for Raw Materials was $6.1 million in Q2 2026, with the low at $3.1 million in Q1 2022.
• Average Raw Materials over 5 years is $4.4 million, with a median of $4.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Raw Materials retreated 10.53% in 2022, then jumped 40.51% in 2023.
• Over 5 years, Raw Materials stood at $3.5 million in 2022, then rose by 19.04% to $4.2 million in 2023, then climbed by 8.93% to $4.5 million in 2024, then surged by 31.46% to $6.0 million in 2025, then grew by 1.72% to $6.1 million in 2026.
• The last three Raw Materials figures came in at $6.1 million (Q2 2026), $6.0 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.